A Phase 3 interventional study of Vedolizumab SC 108 mg and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 194 sites in 30 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.
Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 7 that started in 2016, is one of 16 in phase 3, and was the 10th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Austria, Belgium and 23 more countries
Ages 18–65
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 644 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 101 across the 39 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 39 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
86 studies in Crohn Disease by Takeda: 12 open now, 14 under way, 7 of them phase 3. Of 66 finished, 37 (56%) have results posted.
Among the 86 studies in Crohn Disease by Takeda, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2016, is one of 25 in phase 3, and was the 17th registered.
Takeda’s Crohn Disease studies by the year they started, since 2000.
5 of the studies testing vedolizumab in Crohn Disease that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies testing vedolizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 86 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
The drug being tested in this study is called vedolizumab SC. Vedolizumab SC is being tested to treat people who have moderate to severely active CD. This study will look at clinical remission, as well as enhanced clinical response and corticosteroid-free remission in participants with CD who receive vedolizumab SC maintenance therapy after having achieved a clinical response to vedolizumab IV induction therapy.
The study will enroll approximately 824 participants. All participants will enter a 6 week Induction Phase where they will be administered open-label vedolizumab IV 300 mg via IV infusion at Week 0 (Day 1) and Week 2 (Day 15), and will then be assessed for a clinical response at Week 6. Participants who achieve a clinical response at Week 6 will be randomly assigned to one of the two treatment groups:
Participants who do not achieve a clinical response will not be randomized into the Maintenance Period, and instead will receive a third infusion of vedolizumab IV 300 mg at Week 6.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 71 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderately to severely active CD as determined by a CDAI score of 220 to 450 and 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50
Drug: Vedolizumab SC 108 mg · Drug: Vedolizumab IV 300 mg
Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15) Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50
Drug: Placebo · Drug: Vedolizumab IV 300 mg
Vedolizumab SC Injection.
Vedolizumab placebo-matching SC injection.
Vedolizumab IV Injection.
Percentage of Participants Achieving Clinical Remission at Week 52
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than or equal to (\<=) 150 at Week 52. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to (=) sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: Week 52
Percentage of Participants Achieving Enhanced Clinical Response at Week 52
Enhanced clinical response is defined as a decrease from Baseline of greater than or equal to (\>=) 100 points in the CDAI score at Week 52. A CDAI is a multi-item instrument which measures severity of active CD monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: Week 52
Percentage of Participants Achieving Corticosteroid-free Remission at Week 52
Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: Week 52
Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52
Clinical remission is defined as CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
Time frame: Week 52
Participants with moderate to severe Crohn's disease (CD) took part in the study at 169 investigative sites in North America, South America, Western/Northern Europe, Central Europe, Eastern Europe, East Asia, and Africa/Australia from 04 Jan 2016 to 06 Aug 2019.
| Milestone | Open-label Induction Phase: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|---|
| Started | 644 | 0 | 0 |
| Completed | 594 | 0 | 0 |
| Not completed | 50 | 0 | 0 |
| Withdrew: Reason not specified | 9 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Adverse event | 16 | 0 | 0 |
| Milestone | Open-label Induction Phase: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|---|
| Started | 0 | 135 | 275 |
| Completed | 0 | 73 | 168 |
| Not completed | 0 | 62 | 107 |
| Withdrew: Adverse event | 0 | 12 | 11 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 43 | 78 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 5 | 14 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than or equal to (\<=) 150 at Week 52. A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score is equal to (=) sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 52 | 34.3 (26.3 to 43.0) | 48.0 (42.0 to 54.1) |
Enhanced clinical response is defined as a decrease from Baseline of greater than or equal to (\>=) 100 points in the CDAI score at Week 52. A CDAI is a multi-item instrument which measures severity of active CD monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|
| Percentage of Participants Achieving Enhanced Clinical Response at Week 52 | 44.8 (36.2 to 53.6) | 52.0 (45.9 to 58.0) |
Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|
| Percentage of Participants Achieving Corticosteroid-free Remission at Week 52 | 18.2 (8.2 to 32.7) | 45.3 (35.0 to 55.8) |
Clinical remission is defined as CDAI score \<=150 at Week 52. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
| percentage of participants | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|
| Percentage of TNF-alpha Antagonist Naive Participants Achieving Clinical Remission at Week 52 | 42.9 (30.5 to 56.0) | 48.6 (38.8 to 58.5) |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to 18 weeks after the last dose of study drug (up to Week 68). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Phase Only: Vedolizumab 300 mg IV | 0/235 (0%) | 39/235 (16.6%) | 40/235 (17%) |
| Maintenance Phase: Induction IV + Placebo | 0/134 (0%) | 14/134 (10.4%) | 54/134 (40.3%) |
| Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | 0/275 (0%) | 23/275 (8.4%) | 102/275 (37.1%) |
| Event | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 14/235 | 5/134 | 6/275 |
| Abdominal abscessInfections and infestations | 4/235 | 0/134 | 0/275 |
| Small intestinal obstructionGastrointestinal disorders | 1/235 | 2/134 | 1/275 |
| Anal abscessInfections and infestations | 2/235 | 1/134 | 1/275 |
| Abdominal painGastrointestinal disorders | 2/235 | 0/134 | 0/275 |
| AnaemiasBlood and lymphatic system disorders | 1/235 | 1/134 | 1/275 |
| LeukocytosisBlood and lymphatic system disorders | 0/235 | 1/134 | 0/275 |
| PancreatitisGastrointestinal disorders | 0/235 | 1/134 | 0/275 |
| Anal fistulaGastrointestinal disorders | 1/235 | 1/134 | 1/275 |
| Enterovesical fistulaGastrointestinal disorders | 0/235 | 1/134 | 0/275 |
| Event | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 7/235 | 23/134 | 36/275 |
| NasopharyngitisInfections and infestations | 7/235 | 6/134 | 25/275 |
| Abdominal painGastrointestinal disorders | 9/235 | 11/134 | 21/275 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/235 | 9/134 | 17/275 |
| Upper respiratory tract infectionInfections and infestations | 2/235 | 5/134 | 17/275 |
| HeadacheNervous system disorders | 10/235 | 5/134 | 15/275 |
| NauseaGastrointestinal disorders | 9/235 | 7/134 | 11/275 |
| VomitingGastrointestinal disorders | 4/235 | 7/134 | 6/275 |
The safety analysis set-combined (SAF-C) included all participants who received at least 1 dose of study vedolizumab IV.
| Age, Continuous(years) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Mean | 37.4 ± 12.79 | 36.1 ± 12.93 | 38.2 ± 13.85 | 37.5 ± 13.29 |
| Sex: Female, Male(Participants) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Female | 119 | 68 | 118 | 305 |
| Male | 116 | 66 | 157 | 339 |
| Ethnicity (NIH/OMB)(Participants) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 50 | 20 | 60 | 130 |
| Unknown or Not Reported | 185 | 113 | 213 | 511 |
| Race (NIH/OMB)(Participants) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 2 |
| Asian | 23 | 6 | 17 | 46 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 3 |
| Black or African American | 3 | 1 | 7 | 11 |
| White | 207 | 124 | 250 | 581 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kilogram (kg)) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Mean | 69.94 ± 18.403 | 69.79 ± 18.103 | 74.08 ± 18.994 | 71.68 ± 18.684 |
| Body Mass Index(kilogram per square meter (kg/m^2)) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Mean | 24.20 ± 6.073 | 23.93 ± 5.541 | 25.06 ± 5.915 | 24.51 ± 5.909 |
| Smoking Classification(Participants) | Induction Phase Only: Vedolizumab 300 mg IV | Maintenance Phase: Induction IV + Placebo | Maintenance Phase: Induction IV + Vedolizumab 108 mg SC | Total |
|---|---|---|---|---|
| Never smoked | 140 | 85 | 148 | 373 |
| Current smoker | 49 | 26 | 54 | 129 |
| Ex-smoker | 46 | 23 | 73 | 142 |
Showing the first 100 of 194 sites across 30 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2016 to primary completion in May 2019, 40 months.
Results were first posted in Jun 2020, 1 year 1 month after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 40 months is below that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab